NCT07315750 2026-01-21A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RemeGen Co., Ltd.Phase 3 Recruiting555 enrolled
NCT06793917 2025-07-20Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaFujian Cancer HospitalPhase 3 Recruiting269 enrolled